Automatic Ticket Machine
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global Recombinant Protein Drugs Market Research Report 2023
1 Recombinant Protein Drugs Market Overview
1.1 Product Overview and Scope of Recombinant Protein Drugs
1.2 Recombinant Protein Drugs Segment by Type
1.2.1 Global Recombinant Protein Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Recombinant DNA
1.2.3 Recombinant RNA
1.3 Recombinant Protein Drugs Segment by Application
1.3.1 Global Recombinant Protein Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Pharmaceutical Industry
1.3.3 Others
1.4 Global Recombinant Protein Drugs Market Size Estimates and Forecasts
1.4.1 Global Recombinant Protein Drugs Revenue 2017-2028
1.4.2 Global Recombinant Protein Drugs Sales 2017-2028
1.4.3 Recombinant Protein Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Recombinant Protein Drugs Market Competition by Manufacturers
2.1 Global Recombinant Protein Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Recombinant Protein Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Recombinant Protein Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Recombinant Protein Drugs Manufacturing Sites, Area Served, Product Type
2.5 Recombinant Protein Drugs Market Competitive Situation and Trends
2.5.1 Recombinant Protein Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Recombinant Protein Drugs Players Market Share by Revenue
2.5.3 Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Protein Drugs Retrospective Market Scenario by Region
3.1 Global Recombinant Protein Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Recombinant Protein Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Recombinant Protein Drugs Market Facts & Figures by Country
3.3.1 North America Recombinant Protein Drugs Sales by Country
3.3.2 North America Recombinant Protein Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Recombinant Protein Drugs Market Facts & Figures by Country
3.4.1 Europe Recombinant Protein Drugs Sales by Country
3.4.2 Europe Recombinant Protein Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Recombinant Protein Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Recombinant Protein Drugs Sales by Region
3.5.2 Asia Pacific Recombinant Protein Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Recombinant Protein Drugs Market Facts & Figures by Country
3.6.1 Latin America Recombinant Protein Drugs Sales by Country
3.6.2 Latin America Recombinant Protein Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Recombinant Protein Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Recombinant Protein Drugs Sales by Country
3.7.2 Middle East and Africa Recombinant Protein Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Recombinant Protein Drugs Historic Market Analysis by Type
4.1 Global Recombinant Protein Drugs Sales Market Share by Type (2017-2022)
4.2 Global Recombinant Protein Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Recombinant Protein Drugs Price by Type (2017-2022)
5 Global Recombinant Protein Drugs Historic Market Analysis by Application
5.1 Global Recombinant Protein Drugs Sales Market Share by Application (2017-2022)
5.2 Global Recombinant Protein Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Recombinant Protein Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Novo Nordisk Recombinant Protein Drugs Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Amgen Recombinant Protein Drugs Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi Recombinant Protein Drugs Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Eli Lilly
6.4.1 Eli Lilly Corporation Information
6.4.2 Eli Lilly Description and Business Overview
6.4.3 Eli Lilly Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Eli Lilly Recombinant Protein Drugs Product Portfolio
6.4.5 Eli Lilly Recent Developments/Updates
6.5 Merck Serono
6.5.1 Merck Serono Corporation Information
6.5.2 Merck Serono Description and Business Overview
6.5.3 Merck Serono Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Merck Serono Recombinant Protein Drugs Product Portfolio
6.5.5 Merck Serono Recent Developments/Updates
6.6 Ortho Biotech
6.6.1 Ortho Biotech Corporation Information
6.6.2 Ortho Biotech Description and Business Overview
6.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Ortho Biotech Recombinant Protein Drugs Product Portfolio
6.6.5 Ortho Biotech Recent Developments/Updates
6.7 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Roche Recombinant Protein Drugs Product Portfolio
6.7.5 Roche Recent Developments/Updates
6.8 Kyowa Hakko Kirin
6.8.1 Kyowa Hakko Kirin Corporation Information
6.8.2 Kyowa Hakko Kirin Description and Business Overview
6.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Kyowa Hakko Kirin Recombinant Protein Drugs Product Portfolio
6.8.5 Kyowa Hakko Kirin Recent Developments/Updates
6.9 Pharmingen
6.9.1 Pharmingen Corporation Information
6.9.2 Pharmingen Description and Business Overview
6.9.3 Pharmingen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Pharmingen Recombinant Protein Drugs Product Portfolio
6.9.5 Pharmingen Recent Developments/Updates
6.10 Abcam
6.10.1 Abcam Corporation Information
6.10.2 Abcam Description and Business Overview
6.10.3 Abcam Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Abcam Recombinant Protein Drugs Product Portfolio
6.10.5 Abcam Recent Developments/Updates
6.11 GenSci
6.11.1 GenSci Corporation Information
6.11.2 GenSci Recombinant Protein Drugs Description and Business Overview
6.11.3 GenSci Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 GenSci Recombinant Protein Drugs Product Portfolio
6.11.5 GenSci Recent Developments/Updates
6.12 SL PHARM
6.12.1 SL PHARM Corporation Information
6.12.2 SL PHARM Recombinant Protein Drugs Description and Business Overview
6.12.3 SL PHARM Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.12.4 SL PHARM Recombinant Protein Drugs Product Portfolio
6.12.5 SL PHARM Recent Developments/Updates
6.13 Dongbao Pharm
6.13.1 Dongbao Pharm Corporation Information
6.13.2 Dongbao Pharm Recombinant Protein Drugs Description and Business Overview
6.13.3 Dongbao Pharm Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Dongbao Pharm Recombinant Protein Drugs Product Portfolio
6.13.5 Dongbao Pharm Recent Developments/Updates
6.14 Ankebio
6.14.1 Ankebio Corporation Information
6.14.2 Ankebio Recombinant Protein Drugs Description and Business Overview
6.14.3 Ankebio Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Ankebio Recombinant Protein Drugs Product Portfolio
6.14.5 Ankebio Recent Developments/Updates
6.15 NCPC
6.15.1 NCPC Corporation Information
6.15.2 NCPC Recombinant Protein Drugs Description and Business Overview
6.15.3 NCPC Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.15.4 NCPC Recombinant Protein Drugs Product Portfolio
6.15.5 NCPC Recent Developments/Updates
6.16 Heng Rui
6.16.1 Heng Rui Corporation Information
6.16.2 Heng Rui Recombinant Protein Drugs Description and Business Overview
6.16.3 Heng Rui Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Heng Rui Recombinant Protein Drugs Product Portfolio
6.16.5 Heng Rui Recent Developments/Updates
7 Recombinant Protein Drugs Manufacturing Cost Analysis
7.1 Recombinant Protein Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Recombinant Protein Drugs
7.4 Recombinant Protein Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Recombinant Protein Drugs Distributors List
8.3 Recombinant Protein Drugs Customers
9 Recombinant Protein Drugs Market Dynamics
9.1 Recombinant Protein Drugs Industry Trends
9.2 Recombinant Protein Drugs Market Drivers
9.3 Recombinant Protein Drugs Market Challenges
9.4 Recombinant Protein Drugs Market Restraints
10 Global Market Forecast
10.1 Recombinant Protein Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Recombinant Protein Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Recombinant Protein Drugs by Type (2023-2028)
10.2 Recombinant Protein Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Recombinant Protein Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Recombinant Protein Drugs by Application (2023-2028)
10.3 Recombinant Protein Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Recombinant Protein Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Recombinant Protein Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Recombinant Protein Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Doses) & (US$ Million)
Table 2. Global Recombinant Protein Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Doses) & (US$ Million)
Table 3. Global Recombinant Protein Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Recombinant Protein Drugs Market Competitive Situation by Manufacturers in 2021
Table 5. Global Recombinant Protein Drugs Sales (K Doses) of Key Manufacturers (2017-2022)
Table 6. Global Recombinant Protein Drugs Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Recombinant Protein Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Recombinant Protein Drugs Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Recombinant Protein Drugs Average Price (USD/Dose) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Recombinant Protein Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Recombinant Protein Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Recombinant Protein Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Protein Drugs as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Recombinant Protein Drugs Sales by Region (2017-2022) & (K Doses)
Table 16. Global Recombinant Protein Drugs Sales Market Share by Region (2017-2022)
Table 17. Global Recombinant Protein Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Recombinant Protein Drugs Revenue Market Share by Region (2017-2022)
Table 19. North America Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 20. North America Recombinant Protein Drugs Sales Market Share by Country (2017-2022)
Table 21. North America Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Recombinant Protein Drugs Revenue Market Share by Country (2017-2022)
Table 23. Europe Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 24. Europe Recombinant Protein Drugs Sales Market Share by Country (2017-2022)
Table 25. Europe Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Recombinant Protein Drugs Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Recombinant Protein Drugs Sales by Region (2017-2022) & (K Doses)
Table 28. Asia Pacific Recombinant Protein Drugs Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Recombinant Protein Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Recombinant Protein Drugs Revenue Market Share by Region (2017-2022)
Table 31. Latin America Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 32. Latin America Recombinant Protein Drugs Sales Market Share by Country (2017-2022)
Table 33. Latin America Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Recombinant Protein Drugs Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 36. Middle East and Africa Recombinant Protein Drugs Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Recombinant Protein Drugs Revenue Market Share by Country (2017-2022)
Table 39. Global Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 40. Global Recombinant Protein Drugs Sales Market Share by Type (2017-2022)
Table 41. Global Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Recombinant Protein Drugs Revenue Share by Type (2017-2022)
Table 43. Global Recombinant Protein Drugs Price by Type (2017-2022) & (USD/Dose)
Table 44. Global Recombinant Protein Drugs Sales (K Doses) by Application (2017-2022)
Table 45. Global Recombinant Protein Drugs Sales Market Share by Application (2017-2022)
Table 46. Global Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Recombinant Protein Drugs Revenue Share by Application (2017-2022)
Table 48. Global Recombinant Protein Drugs Price by Application (2017-2022) & (USD/Dose)
Table 49. Novo Nordisk Corporation Information
Table 50. Novo Nordisk Description and Business Overview
Table 51. Novo Nordisk Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 52. Novo Nordisk Recombinant Protein Drugs Product
Table 53. Novo Nordisk Recent Developments/Updates
Table 54. Amgen Corporation Information
Table 55. Amgen Description and Business Overview
Table 56. Amgen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 57. Amgen Recombinant Protein Drugs Product
Table 58. Amgen Recent Developments/Updates
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Business Overview
Table 61. Sanofi Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 62. Sanofi Recombinant Protein Drugs Product
Table 63. Sanofi Recent Developments/Updates
Table 64. Eli Lilly Corporation Information
Table 65. Eli Lilly Description and Business Overview
Table 66. Eli Lilly Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 67. Eli Lilly Recombinant Protein Drugs Product
Table 68. Eli Lilly Recent Developments/Updates
Table 69. Merck Serono Corporation Information
Table 70. Merck Serono Description and Business Overview
Table 71. Merck Serono Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 72. Merck Serono Recombinant Protein Drugs Product
Table 73. Merck Serono Recent Developments/Updates
Table 74. Ortho Biotech Corporation Information
Table 75. Ortho Biotech Description and Business Overview
Table 76. Ortho Biotech Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 77. Ortho Biotech Recombinant Protein Drugs Product
Table 78. Ortho Biotech Recent Developments/Updates
Table 79. Roche Corporation Information
Table 80. Roche Description and Business Overview
Table 81. Roche Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 82. Roche Recombinant Protein Drugs Product
Table 83. Roche Recent Developments/Updates
Table 84. Kyowa Hakko Kirin Corporation Information
Table 85. Kyowa Hakko Kirin Description and Business Overview
Table 86. Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 87. Kyowa Hakko Kirin Recombinant Protein Drugs Product
Table 88. Kyowa Hakko Kirin Recent Developments/Updates
Table 89. Pharmingen Corporation Information
Table 90. Pharmingen Description and Business Overview
Table 91. Pharmingen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 92. Pharmingen Recombinant Protein Drugs Product
Table 93. Pharmingen Recent Developments/Updates
Table 94. Abcam Corporation Information
Table 95. Abcam Description and Business Overview
Table 96. Abcam Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 97. Abcam Recombinant Protein Drugs Product
Table 98. Abcam Recent Developments/Updates
Table 99. GenSci Corporation Information
Table 100. GenSci Description and Business Overview
Table 101. GenSci Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 102. GenSci Recombinant Protein Drugs Product
Table 103. GenSci Recent Developments/Updates
Table 104. SL PHARM Corporation Information
Table 105. SL PHARM Description and Business Overview
Table 106. SL PHARM Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 107. SL PHARM Recombinant Protein Drugs Product
Table 108. SL PHARM Recent Developments/Updates
Table 109. Dongbao Pharm Corporation Information
Table 110. Dongbao Pharm Description and Business Overview
Table 111. Dongbao Pharm Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 112. Dongbao Pharm Recombinant Protein Drugs Product
Table 113. Dongbao Pharm Recent Developments/Updates
Table 114. Ankebio Corporation Information
Table 115. Ankebio Description and Business Overview
Table 116. Ankebio Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 117. Ankebio Recombinant Protein Drugs Product
Table 118. Ankebio Recent Developments/Updates
Table 119. NCPC Corporation Information
Table 120. NCPC Description and Business Overview
Table 121. NCPC Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 122. NCPC Recombinant Protein Drugs Product
Table 123. NCPC Recent Developments/Updates
Table 124. Heng Rui Corporation Information
Table 125. Heng Rui Description and Business Overview
Table 126. Heng Rui Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 127. Heng Rui Recombinant Protein Drugs Product
Table 128. Heng Rui Recent Developments/Updates
Table 129. Production Base and Market Concentration Rate of Raw Material
Table 130. Key Suppliers of Raw Materials
Table 131. Recombinant Protein Drugs Distributors List
Table 132. Recombinant Protein Drugs Customers List
Table 133. Recombinant Protein Drugs Market Trends
Table 134. Recombinant Protein Drugs Market Drivers
Table 135. Recombinant Protein Drugs Market Challenges
Table 136. Recombinant Protein Drugs Market Restraints
Table 137. Global Recombinant Protein Drugs Sales Forecast by Type (2023-2028) & (K Doses)
Table 138. Global Recombinant Protein Drugs Sales Market Share Forecast by Type (2023-2028)
Table 139. Global Recombinant Protein Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 140. Global Recombinant Protein Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 141. Global Recombinant Protein Drugs Sales Forecast by Application (2023-2028) & (K Doses)
Table 142. Global Recombinant Protein Drugs Sales Market Share Forecast by Application (2023-2028)
Table 143. Global Recombinant Protein Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 144. Global Recombinant Protein Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 145. Global Recombinant Protein Drugs Sales Forecast by Region (2023-2028) & (K Doses)
Table 146. Global Recombinant Protein Drugs Sales Market Share Forecast by Region (2023-2028)
Table 147. Global Recombinant Protein Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 148. Global Recombinant Protein Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Protein Drugs
Figure 2. Global Recombinant Protein Drugs Market Share by Type in 2021 & 2028
Figure 3. Recombinant DNA Product Picture
Figure 4. Recombinant RNA Product Picture
Figure 5. Global Recombinant Protein Drugs Market Share by Application in 2021 & 2028
Figure 6. Pharmaceutical Industry
Figure 7. Others
Figure 8. Global Recombinant Protein Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Recombinant Protein Drugs Market Size (2017-2028) & (US$ Million)
Figure 10. Global Recombinant Protein Drugs Sales (2017-2028) & (K Doses)
Figure 11. Recombinant Protein Drugs Sales Share by Manufacturers in 2021
Figure 12. Global Recombinant Protein Drugs Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Recombinant Protein Drugs Players: Market Share by Revenue in 2021
Figure 14. Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Recombinant Protein Drugs Sales Market Share by Region (2017-2022)
Figure 16. Global Recombinant Protein Drugs Sales Market Share by Region in 2021
Figure 17. Global Recombinant Protein Drugs Revenue Market Share by Region (2017-2022)
Figure 18. Global Recombinant Protein Drugs Revenue Market Share by Region in 2021
Figure 19. U.S. Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Taiwan Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Philippines Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Vietnam Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Turkey Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Saudi Arabia Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. U.A.E Recombinant Protein Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Sales Market Share of Recombinant Protein Drugs by Type (2017-2022)
Figure 44. Manufacturing Cost Structure of Recombinant Protein Drugs
Figure 45. Manufacturing Process Analysis of Recombinant Protein Drugs
Figure 46. Recombinant Protein Drugs Industrial Chain Analysis
Figure 47. Channels of Distribution
Figure 48. Distributors Profiles
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novo Nordisk Amgen Sanofi Eli Lilly Merck Serono Ortho Biotech Roche Kyowa Hakko Kirin Pharmingen Abcam GenSci SL PHARM Dongbao Pharm Ankebio NCPC Heng Rui